ArticleJournal of thoracic disease2025
Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Real-world survival patterns and multimodal therapy utilization in small cell lung cancer: a retrospective cohort study in a Chinese countryside hospital.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Given the high invasiveness of extensive-stage small-cell lung cancer (ES-SCLC), the limited treatment options available, and the definite efficacy of poly ADP-ribose polymerase inhibitors (PARPis) in the treatment of diverse cancers, such as metastatic castration-resistant prostate cancer, recurrent ovarian cancer, and advanced breast cancer, we performed a meta-analysis to evaluate the efficacy and toxicity of PARPis in the treatment of ES-SCLC. Methods: A systematic literature search of online databases was conducted to retrieve relevant articles published before March 2025. Six articles on randomized controlled trials (RCTs) involving 924 patients were included in the meta-analysis. The relative risk (RR)/odds ratio (OR) data were extracted from the RCTs as the research objects to conduct an integrated analysis via RevMan5.4. Results: The meta-analysis illustrated that PARPis significantly improved the objective response rate (ORR) [OR =2.03, 95% confidence interval (CI): 1.26-3.28] and progression-free survival (PFS) [hazard ratio (HR) =0.72, 95% CI: 0.63-0.81] of the ES-SCLC patients between the included 6 RCTS, especially those with Conclusions: Our findings confirmed that PARPis represent an effective treatment option for ES-SCLC patients, especially those with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.